Keros Therapeutics, Inc. — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Keros Therapeutics announced first patient dosing in a Phase 2 open-label, multi-cohort basket trial of rinvatercept in Duchenne muscular dystrophy (DMD) patients, with primary endpoints of safety and tolerability in late-ambulatory and early non-ambulatory patients. Initial data is expected in H1 2027. No financial terms, partnership details, or fundraising amounts are disclosed.
Why this rating
Clinical milestone advances pipeline; moderate importance for clinical-stage biotech. Data 6+ months away; outcome uncertain. No material financing or partnership revealed.
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.